retatrutide phase 3 trial results are in. TRIUMPH-1 topline: 28.3% average weight loss at 80 weeks, 30.3% at 104 weeks in participants with BMI 35 or higher. That averages 85 lbs. No pharmaceutical retatrutide maximum dose clinical trials

IgG is a type of antibody, considered a crucial component of the immune system that apparently mediates various inflammatory processes

Multiparameter peptide optimization toward stable triple agonists for the treatment of diabetes and obesity

Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Bjorklund AC, Augsten M et al

Mechanistically, T3 acts to alter the BA composition by targeting CYP8B1, a sterol 12-hydroxylase required for CA synthesis, and then the subsequently altered BA profiles, particularly the increased non-12-OH FXR-antagonistic BAs, potentiates the GLP-1 production and insulin secretion by repressing FXR signaling

Dungan & DeSantis, 2026)

GLP-1 induces the ileal brake phenomenon by inhibition of gastric emptying and intestinal transit time